AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33328333 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2/UFKA-20 complexes
Number of subjects: 0
Study 36301013 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention (VD)
Number of subjects: 291
Study 36301013 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral counselling (OR)
Number of subjects: 291
Study 36301013 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral counselling with App (OR + App)
Number of subjects: 291
Study 36301013 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with App (VD + App)
Number of subjects: 291
Study 36301013 — intervention group
Group type: COMPARATOR
Intervention: Oral counselling without App (OR without App)
Number of subjects: 291
Study 36301013 — intervention group
Group type: COMPARATOR
Intervention: Video without App (VD without App)
Number of subjects: 291
Study 33938493 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI FUDR + SYS FOLFIRI + Pmab
Number of subjects: 75
Study 33938493 — intervention group
Group type: COMPARATOR
Intervention: HAI FUDR + SYS FOLFIRI
Number of subjects: 75
Study 35930415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored parenting plans generated by a computerized algorithm based on participants' responses to the Sickle Cell Reproductive Health Knowledge Parenting Intent Questionnaire.
Number of subjects: 0
Study 35930415 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based genetic inheritance education (as a context for the intervention).
Number of subjects: 0
Study 32748630 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS (10 Hz, 700 pulses for four weeks)
Number of subjects: 60
Study 36410806 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise individually titrated increase of dialysate magnesium concentration from 0.50 to 0.75 to 1.00 mmol/L during 8 weeks
Number of subjects: 53
Study 36410806 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate magnesium concentration of 0.50 mmol/L
Number of subjects: 53
Study 32084330 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation at 18 CpGs
Number of subjects: 400102
Study 32084330 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation at three specific CpGs (cg21201401, cg19758448, cg12616487)
Number of subjects: 400102
Study 32084330 — intervention group
Group type: COMPARATOR
Intervention: DNA methylation mediation
Number of subjects: 400102
Study 32084330 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared causal variants analysis using 'moloc' framework
Number of subjects: 400102
Study 36178575 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 10 lymph node dissections (LNDs)
Number of subjects: 26517
Study 36178575 — intervention group
Group type: COMPARATOR
Intervention: ≤ 9 lymph node dissections (LNDs)
Number of subjects: 26517
Study 34319514 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen gas inhalation (6.5 vol% in 2 L/min of mixed air) for 16 weeks, twice a day for 1 hour
Number of subjects: 20
Study 34319514 — intervention group
Group type: COMPARATOR
Intervention: Placebo air inhalation for 16 weeks, twice a day for 1 hour
Number of subjects: 20
Study 34319514 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen gas inhalation
Number of subjects: 20
Study 33032806 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anesthesia
Number of subjects: 105
Study 33032806 — intervention group
Group type: COMPARATOR
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 105
Study 35279301 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally developed dental implants (test group)
Number of subjects: 136
Study 35279301 — intervention group
Group type: COMPARATOR
Intervention: Imported dental implants (control group)
Number of subjects: 136
Study 33200812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of 10 mg rosuvastatin and ezetimibe administered in the morning for 6 weeks
Number of subjects: 83
Study 33200812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of 10 mg rosuvastatin and ezetimibe administered in the evening for 6 weeks
Number of subjects: 83
Study 33200812 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of the drug
Number of subjects: 83
Study 33200812 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening administration of the drug
Number of subjects: 83
Study 33200812 — intervention group
Group type: COMPARATOR
Intervention: Morning vs Evening drug administration
Number of subjects: 83
Study 36109314 — intervention group
Group type: EXPERIMENTAL
Intervention: Grooved ureteral stent
Number of subjects: 42
Study 36109314 — intervention group
Group type: COMPARATOR
Intervention: Smooth-walled ureteral stent
Number of subjects: 42
Study 33229339 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental calcium (1,200 mg/day) and/or vitamin D3 (1,000 IU/day)
Number of subjects: 175
Study 33229339 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 175
Study 36104929 — intervention group
Group type: EXPERIMENTAL
Intervention: DT catheter (50 W, 9 s)
Number of subjects: 113
Study 36104929 — intervention group
Group type: COMPARATOR
Intervention: AI-guided ablation (AI anterior 550; AI posterior 400)
Number of subjects: 113
Study 34199006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy-based product (DP) containing protein, galacto-oligosaccharides, vitamins, and minerals, consumed 1 hour before bedtime for three weeks
Number of subjects: 70
Study 34199006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy-based product (DP)
Number of subjects: 70
Study 34199006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (skimmed milk)
Number of subjects: 70
Study 34619378 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with remifentanil (Group D: n=25)
Number of subjects: 50
Study 34619378 — intervention group
Group type: COMPARATOR
Intervention: Propofol with remifentanil (Group P: n=25)
Number of subjects: 50
Study 33675289 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified educational webinar
Number of subjects: 52
Study 33675289 — intervention group
Group type: COMPARATOR
Intervention: Non-gamified educational webinar
Number of subjects: 52
Study 32736622 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care (ANC)
Number of subjects: 3758
Study 32736622 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery care
Number of subjects: 3758
Study 32736622 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal care (PNC)
Number of subjects: 3758
Study 32736622 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternity waiting homes (MWH)
Number of subjects: 3758
Study 34519446 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC intervention Fall prevention
Number of subjects: 118
Study 33328161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 0
Study 33328161 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 33328161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35101110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy, off-label subretinal TPA up to 25 μg in 0.25 ml, intravitreal 20% sulfahexafluoride gas, and intravitreal aflibercept.
Number of subjects: 210
Study 35101110 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal aflibercept monotherapy.
Number of subjects: 210
Study 35101110 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received intravitreal aflibercept 2 mg administered monthly for 3 doses, then 2-monthly to month 12.
Number of subjects: 210
Study 33738656 — intervention group
Group type: EXPERIMENTAL
Intervention: Two courses of DCF (70 mg/m2 intravenous docetaxel and 70 mg/m2 intravenous cisplatin on day 1, and a continuous 700 mg/m2 fluorouracil infusion for 5 days) every 3 weeks
Number of subjects: 180
Study 33738656 — intervention group
Group type: COMPARATOR
Intervention: Three courses of DCF (70 mg/m2 intravenous docetaxel and 70 mg/m2 intravenous cisplatin on day 1, and a continuous 700 mg/m2 fluorouracil infusion for 5 days) every 3 weeks
Number of subjects: 180
Study 32230729 — intervention group
Group type: EXPERIMENTAL
Intervention: High-γ-PGA natto meal (WR + high-γ-PGA natto)
Number of subjects: 0
Study 32230729 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-γ-PGA natto meal (WR + low-γ-PGA natto)
Number of subjects: 0
Study 32230729 — intervention group
Group type: COMPARATOR
Intervention: White rice (WR)
Number of subjects: 0
Study 35014069 — intervention group
Group type: EXPERIMENTAL
Intervention: ALKS 7119 (≥50 mg)
Number of subjects: 100
Study 32472307 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 95
Study 32472307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 32723670 — intervention group
Group type: EXPERIMENTAL
Intervention: SPN-812 100 mg/day
Number of subjects: 477
Study 32723670 — intervention group
Group type: EXPERIMENTAL
Intervention: SPN-812 200 mg/day
Number of subjects: 477
Study 32723670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 34653384 — intervention group
Group type: EXPERIMENTAL
Intervention: Poloxamer 407-based 0.75% ropivacaine hydrogel (22.5 mg)
Number of subjects: 89
Study 34653384 — intervention group
Group type: COMPARATOR
Intervention: Continuous thoracic paravertebral block using On‐Q (0.2% ropivacaine, 4 mg/h for 48 hours)
Number of subjects: 89
Study 33661917 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum tricosanoyl sphingomyelin (d18:1/23:0) levels
Number of subjects: 50
Study 33661917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sixteen metabolites including cotinine, N‐delta‐acetylornithine, and sphingomyelin (d17:1/24:1)
Number of subjects: 50
Study 33661917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingolipid markers
Number of subjects: 50
Study 33661917 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants in sphingolipid pathway genes
Number of subjects: 50
Study 33661917 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigenomic analyses
Number of subjects: 50
Study 33549435 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet
Number of subjects: 24
Study 33549435 — intervention group
Group type: COMPARATOR
Intervention: High Carbohydrate (HC) diet
Number of subjects: 24
Study 35277540 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab
Number of subjects: 8844
Study 34608329 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir 54 mg
Number of subjects: 16
Study 34608329 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir 62 mg
Number of subjects: 16
Study 34608329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32847980 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 0
Study 32847980 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC count pre-cycle 1
Number of subjects: 0
Study 32847980 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC count post-treatment
Number of subjects: 0
Study 32847980 — intervention group
Group type: EXPERIMENTAL
Intervention: Declination in CTCs
Number of subjects: 0
Study 35363262 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (FFX)
Number of subjects: 0
Study 32056982 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-m sprint
Number of subjects: 13
Study 32056982 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-m sprint
Number of subjects: 13
Study 35142582 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab-based triplet therapies (VGPR or better)
Number of subjects: 883
Study 35142582 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab-based triplet therapies (MRD negativity)
Number of subjects: 883
Study 32365314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime orthosis on the second or third finger of the dominant hand
Number of subjects: 52
Study 32365314 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 52
Study 33216196 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 10 mg/kg/day, orally
Number of subjects: 78
Study 33216196 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 10 U/kg/day, orally
Number of subjects: 78
Study 33216196 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 33444565 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 IU monthly)
Number of subjects: 21315
Study 33444565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21315
Study 32476800 — intervention group
Group type: EXPERIMENTAL
Intervention: HR‐T2WI
Number of subjects: 118
Study 32476800 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 118
Study 32476800 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE‐T1
Number of subjects: 118
Study 32476800 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC
Number of subjects: 118
Study 32476800 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐modal radiomics model
Number of subjects: 118
Study 32476800 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical radiomics nomogram
Number of subjects: 118
Study 33548908 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg once daily for 12 weeks
Number of subjects: 300
Study 32438012 — intervention group
Group type: EXPERIMENTAL
Intervention: Purdue Pegboard Test (PPT)
Number of subjects: 27
Study 32438012 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip force task
Number of subjects: 27
Study 32438012 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI activity in sensorimotor areas
Number of subjects: 27
Study 35981821 — intervention group
Group type: EXPERIMENTAL
Intervention: Single antiplatelet therapy (SAPT) for 11 months (or 5 months in patients on oral anticoagulation)
Number of subjects: 4579
Study 35981821 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) for ≥2 months followed by SAPT
Number of subjects: 4579
Study 35981821 — intervention group
Group type: COMPARATOR
Intervention: Single antiplatelet therapy (SAPT)
Number of subjects: 4579
Study 33411910 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g/day of fructooligosaccharide (FOS) for 3 months
Number of subjects: 46
Study 33411910 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) for 3 months
Number of subjects: 46
Study 33411910 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic group
Number of subjects: 46
Study 33411910 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46
Study 33411910 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS
Number of subjects: 46
Study 32199491 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd3‐EBO‐Z
Number of subjects: 3013
Study 32199491 — intervention group
Group type: COMPARATOR
Intervention: Placebo/ChAd3‐EBO‐Z
Number of subjects: 3013
Study 35360270 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nursing (intervention group)
Number of subjects: 82
Study 35360270 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing (control group)
Number of subjects: 82
Study 32929612 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8232
Number of subjects: 0
Study 32929612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34022365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenotomy
Number of subjects: 114
Study 34022365 — intervention group
Group type: COMPARATOR
Intervention: Tenodesis
Number of subjects: 114
Study 32207575 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/ml tranexamic acid (TXA)
Number of subjects: 202
Study 32207575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 202
Study 36352399 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-controlled Laminar Airflow (TLA)
Number of subjects: 226
Study 36352399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 34836014 — intervention group
Group type: EXPERIMENTAL
Intervention: ASI + I (Inositol‐enhanced bonded arginine silicate) 1600 mg
Number of subjects: 26
Study 37661604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryomodulation treatment (10-min controlled cooling)
Number of subjects: 0
Study 37661604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryomodulation treatment
Number of subjects: 0
Study 34241762 — intervention group
Group type: EXPERIMENTAL
Intervention: Low genistein doses (10 µg/g body weight)
Number of subjects: 300
Study 34241762 — intervention group
Group type: EXPERIMENTAL
Intervention: High genistein doses (100 µg/g body weight)
Number of subjects: 300
Study 34241762 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-estradiol (E2) (10 µg/g body weight)
Number of subjects: 300
Study 34241762 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle only)
Number of subjects: 300
Study 34241762 — intervention group
Group type: COMPARATOR
Intervention: Blank (no injection)
Number of subjects: 300
Study 34962574 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist
Number of subjects: 500
Study 34962574 — intervention group
Group type: EXPERIMENTAL
Intervention: MAO-B inhibitor
Number of subjects: 500
Study 34962574 — intervention group
Group type: COMPARATOR
Intervention: COMT inhibitor
Number of subjects: 500
Study 34962574 — intervention group
Group type: COMPARATOR
Intervention: Dopamine agonist vs MAO-B inhibitors
Number of subjects: 500
Study 34962574 — intervention group
Group type: COMPARATOR
Intervention: Dopamine agonist and MAO-B inhibitors
Number of subjects: 500
Study 33514292 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1144
Study 33514292 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 1144
Study 33514292 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 1144
Study 33085647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar intermittent theta burst stimulation (iTBS), 10-day treatment
Number of subjects: 20
Study 33085647 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 32615020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 97
Study 32615020 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group P)
Number of subjects: 97
Study 32421267 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of emergency patients' information in the hospital information system
Number of subjects: 385
Study 32421267 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuracy
Number of subjects: 385
Study 32421267 — intervention group
Group type: EXPERIMENTAL
Intervention: Completeness
Number of subjects: 385
Study 32421267 — intervention group
Group type: EXPERIMENTAL
Intervention: Timeliness
Number of subjects: 385
Study 32421267 — intervention group
Group type: EXPERIMENTAL
Intervention: Definition
Number of subjects: 385
Study 32421267 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessibility
Number of subjects: 385
Study 35272843 — intervention group
Group type: EXPERIMENTAL
Intervention: Exa Cerapol polishing kit
Number of subjects: 96
Study 35272843 — intervention group
Group type: EXPERIMENTAL
Intervention: Shofu polishing kit
Number of subjects: 96
Study 34274609 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network architecture for estimating left ventricle volume
Number of subjects: 397
Study 34274609 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network segmentation of left ventricle
Number of subjects: 397
Study 34033624 — intervention group
Group type: EXPERIMENTAL
Intervention: COOL (2°C water perfusing a top for 2 min)
Number of subjects: 7
Study 34033624 — intervention group
Group type: COMPARATOR
Intervention: CON (no cooling)
Number of subjects: 7
Study 34033624 — intervention group
Group type: EXPERIMENTAL
Intervention: COOL
Number of subjects: 7
Study 34033624 — intervention group
Group type: COMPARATOR
Intervention: COOL and CON
Number of subjects: 7
Study 35597600 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 0
Study 32330929 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein profiles at birth
Number of subjects: 14
Study 32330929 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein profiles at 1 week postnatally
Number of subjects: 14
Study 32330929 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein profiles up to term-equivalent age
Number of subjects: 14
Study 32330929 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusters of proteins identified
Number of subjects: 14
Study 32266595 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive nomogram and web-based survival rate calculator for cancer-specific survival.
Number of subjects: 2007
Study 32266595 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent risk factors identified: age, race, T stage, N stage, M stage, surgery, radiotherapy, chemotherapy, marital status.
Number of subjects: 2007
Study 33858488 — intervention group
Group type: EXPERIMENTAL
Intervention: Short protocol (20 ECT sessions over 6 months)
Number of subjects: 64
Study 33858488 — intervention group
Group type: COMPARATOR
Intervention: Long protocol (40 ECT sessions over 12 months)
Number of subjects: 64
Study 33151126 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) levels in PD patients
Number of subjects: 500
Study 33151126 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D levels
Number of subjects: 500
Study 32486874 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids plus gabapentinoids
Number of subjects: 1059
Study 32486874 — intervention group
Group type: COMPARATOR
Intervention: Opioids
Number of subjects: 1059
Study 33307555 — intervention group
Group type: EXPERIMENTAL
Intervention: HIITSM (10 HIIT sessions over 13 days)
Number of subjects: 19
Study 33307555 — intervention group
Group type: COMPARATOR
Intervention: HIITTRAD (4 HIIT sessions over 13 days)
Number of subjects: 19
Study 33148502 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA-biofeedback with treatment as usual (BFB + TAU)
Number of subjects: 30
Study 33148502 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study 34850173 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 4619
Study 34850173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4619
Study 34850173 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4619